Please use this identifier to cite or link to this item:
http://repositorio.ufla.br/jspui/handle/1/41535| metadata.artigo.dc.title: | Current treatment approaches for COVID-19 and the clinical value of transfusion-related technologies |
| metadata.artigo.dc.creator: | Li, Ying Liu, Shanglong Zhang, Shuchao Ju, Qiang Zhang, Shaoqiang Yang, Yuanming Wang, Haiyan |
| metadata.artigo.dc.subject: | COVID-19 Convalescent plasma Plasmapheresis Mesenchymal stem cell |
| metadata.artigo.dc.publisher: | Elsevier |
| metadata.artigo.dc.date.issued: | 2020 |
| metadata.artigo.dc.identifier.citation: | LI, Y. et al. Current treatment approaches for COVID-19 and the clinical value of transfusion-related technologies. Transfusion and Apheresis Science, [S.l.], 2020. No prelo. |
| metadata.artigo.dc.description.abstract: | COVID-19 is caused by SARS-CoV-2 which is a new enveloped virus that belongs to the Beta coronavirus genus. As a major health crisis, SARS-CoV-2 has infected over a million people around the world. There is currently no specific treatment available for patients with COVID-19 infection. Numerous potential therapies, including supportive intervention, immunomodulatory agents, antiviral therapy, and convalescent plasma transfusion, have been used in clinical practice. Herein, we summarize the current potential therapeutic approaches for diseases related to COVID-19 infection and discusses the clinical value of blood transfusion-related technologies used in COVID-19 treatment. |
| metadata.artigo.dc.identifier.uri: | http://www.sciencedirect.com/science/article/pii/S1473050220301427 http://repositorio.ufla.br/jspui/handle/1/41535 |
| metadata.artigo.dc.language: | en_US |
| Appears in Collections: | FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19) |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.